Search Results for

Clear All Filters

September 29, 2021 | The American Prospect

Fatou Ndiaye Timi Iwayemi

Op-Ed

CoronavirusForeign PolicyPharmaTrade Policy

How to Vaccinate the World

When United States Trade Representative Katherine Tai announced this past May that the U.S. would support the TRIPS waiver on COVID-19 vaccines at the World Trade Organization (WTO), we at the Revolving Door Project celebrated the administration’s decision as “a transformative, hopeful event.” The waiver proposal calls on the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council to suspend intellectual-property protections on COVID-19 therapeutics, diagnostics, and vaccines to ensure materials necessary for combating the pandemic are “available promptly, in sufficient quantities and at affordable price to meet global demand.”

July 27, 2021 | Washington Monthly

Sion Bell Timi Iwayemi

Op-Ed

cryptocurrencyFinancial RegulationFintech

How to Catch Bitcoin Tax Cheats

Crypto is a global phenomenon, and one with a rapidly growing capacity to upend tax administration worldwide. The U.S. has been slow to act to combat this threat, but clever use of extant unilateral and multilateral laws on information sharing and programs that capitalize on expertise and information outside government provide opportunities for much better protection against tax evasion. If Biden and his administration are committed to closing tax loopholes, they must use every tool available.

July 22, 2021

Timi Iwayemi Fatou Ndiaye

Report

Anti-MonopolyIndependent AgenciesIntellectual PropertyPharmaTrade Policy

The Industry Agenda: Big Pharma

In 2019, Gallup found that the pharmaceutical industry was “the most poorly regarded industry in Americans’ eyes,” and rightfully so. Pharmaceutical companies often set drug prices exorbitantly high, including life-saving drugs which patients literally cannot go without, such as insulin. This includes older drugs that are cheaper to produce — such as epinephrine (emergency medication used to treat severe allergic reactions and asthma attacks). These firms achieve this by stifling competition at the consumer’s expense, jealously protecting their money-makers from the generics which the pharmaceutical system is supposed to develop after a patent expires.

April 27, 2021

Timi Iwayemi

Blog Post

Financial RegulationFintech

The Longer Trump’s Acting Comptroller Stays, The More Damage He’ll Do

Under Otting and Brooks’ leadership, the OCC rolled out rules contrary to its responsibility to maintain a federal banking system that is safe against systemic risks and provides aid to all customers. Now they’re all out of power — but Acting Comptroller, Blake Paulson, whose ascent was ensured by Brooks and Mnuchin, has demonstrated no desire to change course from the path set by Trump’s lackeys. That is why Biden needs to act quickly and appoint a Comptroller who recognizes the dangerous precedent set by the Trump administration.

April 15, 2021

Timi Iwayemi

Blog Post

Foreign PolicyIntellectual Property

Why Is Politico's Ryan Heath Carrying Water For Big Pharma Monopolies?

The world is currently at an inflection point – Western leaders can choose to continue blocking the TRIPS waiver and lock in a cycle of dependence or empower poorer countries to develop generic vaccines and build infrastructure that will safely put the pandemic behind us. Critiques of the TRIPS waiver claim that most poor countries lack the infrastructure to carry out vaccine operations – a paternalistic view that suggests that manufacturing capacity, supply chain management, and logistics are static in nature. The sooner we act, the more time poorer countries have to begin mobilizing resources needed to make generic vaccine development possible.

April 09, 2021

Eleanor Eagan Timi Iwayemi

Blog Post

Department of CommerceIntellectual Property

Why You Should Care Who Leads the Patent and Trademark Office

As pressure mounts on the United States government to support waiving intellectual property (IP) protections on the COVID-19 vaccines at the World Trade Organization, progressives are closely monitoring the Biden administration’s appointments to agencies that impact intellectual property matters such as the United States Patent and Trademark Office (USPTO).

February 11, 2021

Max Moran Timi Iwayemi

Report

2020 Election/TransitionFintech

The Industry Agenda: Fintech

Since fintech apps provide a wide range of financial services, there are many potential harms to leaving the industry largely under-regulated — especially since many fintech and cryptocurrency firms design their products to narrowly evade existing laws that define certain types of financial products, and thus, the regulations to which they are subject.

February 04, 2021 | American Prospect

Dorothy Slater Max Moran Timi Iwayemi

Op-Ed

2020 Election/TransitionClimateDepartment of JusticeFinancial RegulationFintech

Even After The Cabinet Selections, Personnel Is Policy

As grinding as the cabinet fights have been, they’re only the first wave of the Biden administration’s personnel. Now comes a new stage of the transition, in which the newly-named secretaries choose their own undersecretaries and senior advisers. Although occupants of these positions typically operate outside the national spotlight, they still wield enormous power.

February 01, 2021 | The Intercept

Max Moran Timi Iwayemi

Op-Ed

2020 Election/TransitionFinancial RegulationFintech

Robinhood Is A Perfect Example Of Fintech's Insidious Power

Fintech is neither inherently good nor bad; rather, like any technology, its potential impact on society is closely tied to the policy decisions guiding its use — and the next four years could define how much the fintech industry is able to shape the financial system. Left to their own devices, fintech firms could swindle average people through ill-advised day-trading or high-interest loans, usher new systemic risks into the financial system, and develop traceable, privately owned currencies with the potential to replace cash.

January 21, 2021

Timi Iwayemi

Blog Post

2020 Election/TransitionFintechTech

Michael Barr's Past And Present Raise Deep Concerns If Appointed

If appointed to Biden’s OCC, Barr will confront one major new question for the primary federal regulator of banks: how to handle the emergent “fintech” industry of lending and payments apps. Disturbingly, Barr’s history advising and investing in the fintech industry suggests an approach similar to Trump’s own fintech-friendly stooge, former acting Comptroller Brian Brooks.

November 24, 2020

Timi Iwayemi

Blog Post

2020 Election/TransitionForeign PolicyTech

Michèle Flournoy and The Ongoing Influence of WestExec Advisors

As we proposed in the Prospect, Biden’s administration can pursue a progressive national security agenda that prioritizes diplomacy over military action, opposes regime change interventions, reduces the Pentagon’s budget, and condemns governments that violate human rights. But to do so, Biden must also end the defense industry’s influence on the executive branch and turn to individuals without deep conflicts.